Market closedNon-fractional
Lineage Cell Therapeutics/LCTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Lineage Cell Therapeutics
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Ticker
LCTX
Sector
Healthcare
Trading on
AMEX
Industry
Biotechnology
Headquarters
Carlsbad, United States
Employees
72
Website
www.lineagecell.com
LCTX Metrics
BasicAdvanced
$196M
Market cap
-
P/E ratio
-$0.13
EPS
1.31
Beta
-
Dividend rate
Price and volume
Market cap
$196M
Beta
1.31
Financial strength
Current ratio
2.707
Quick ratio
2.587
Long term debt to equity
3.033
Total debt to equity
4.584
Management effectiveness
Return on assets (TTM)
-11.97%
Return on equity (TTM)
-33.76%
Valuation
Price to revenue (TTM)
22.853
Price to book
2.71
Price to tangible book (TTM)
12.91
Price to free cash flow (TTM)
-7.74
Growth
Revenue change (TTM)
-32.48%
Earnings per share change (TTM)
-2.98%
3-year revenue growth (CAGR)
67.50%
3-year earnings per share growth (CAGR)
14.44%
What the Analysts think about LCTX
Analyst Ratings
Majority rating from 6 analysts.
LCTX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.4M
-30.00%
Net income
-$6.5M
38.30%
Profit margin
-464.28%
97.57%
LCTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
-$0.04
-$0.03
-$0.04
-
Expected
-$0.04
-$0.04
-$0.04
-$0.04
-$0.05
Surprise
-32.26%
-6.67%
-30.00%
4.35%
-
LCTX News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lineage Cell Therapeutics stock?
Lineage Cell Therapeutics (LCTX) has a market cap of $196M as of July 27, 2024.
What is the P/E ratio for Lineage Cell Therapeutics stock?
The price to earnings (P/E) ratio for Lineage Cell Therapeutics (LCTX) stock is 0 as of July 27, 2024.
Does Lineage Cell Therapeutics stock pay dividends?
No, Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Lineage Cell Therapeutics dividend payment date?
Lineage Cell Therapeutics (LCTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Lineage Cell Therapeutics?
Lineage Cell Therapeutics (LCTX) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Lineage Cell Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.